剂泰科技-P(07666)今日盘中大涨5.04%，延续了其上市首日的强劲表现。
消息面上，剂泰科技于昨日正式在港交所挂牌上市，成为“全球AI药物递送第一股”及“港股AI大分子生物制药第一股”。公司此次IPO募资总额创下2026年迄今港股医疗健康板块之最，香港公开发售获得超6900倍超额认购，国际配售获得82倍超额认购，市场认购热情极高。
剂泰科技的核心竞争力源于其自主研发的全球首个AI驱动纳米递送平台NanoForge，并基于此开发了多条产品管线。其中，核心产品MTS-004是中国首款完成III期临床的AI赋能制剂新药。公司上市前已完成多轮融资，获得红杉资本等知名机构持续支持，此次IPO还获得了贝莱德、瑞银、高瓴等18家基石投资者认购。这些积极的上市因素和公司基本面增强了市场信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.